Sabinsa has been granted a US patent on the company’s shelf-stable probiotic LactoSpore® (Bacillus coagulans MTCC 5856) for its use for therapeutic management of Irritable Bowel Syndrome (IBS).
Patent No. US9579352 claims a method for managing the symptoms associated with IBS including abdominal pain, bloating or visible distension of abdomen, constipation and loose stools, by orally administering a formulation comprising Bacillus coagulans MTCC 5856 (not less than 2 billion spores) as a dietary supplement along with regular treatment. LactoSpore® ameliorates the symptoms of IBS as seen in a recently published human clinical trial (Majeed et al. Nutrition Journal (2016) 15:21 DOI 10.1186/s12937-016-0140-6). In the study, LactoSpore® demonstrated efficacy in relieving clinical symptoms in IBS patients.
In 2016 Health Canada, the federal department that regulates the products that help the Canadian people maintain and improve their health, issued a Product License to Sabinsa for a significant health claim on LactoSpore® Balance: “Helps relieve abdominal pain associated with IBS (Irritable Bowel Syndrome).”
“Sabinsa’s 136 patents demonstrate the continuous innovation process that Sabinsa proudly brings to its ingredients portfolio,” said Sabinsa Marketing Director Shaheen Majeed. “We deliver not only quality but efficacy as well, and this patent on LactoSpore® delivers on that focus.”